The framework for investigating the CDH17 profile in CRC and its relationship with clinicopathological characteristics was expanded by including patient survival as a major endpoint for assessing the prognostic influence of this biomarker on tumor behavior. This evidence concerns the gene CDH17 and colorectal carcinoma.